Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ROTATE-1 albuminuria response crossover trial in type 1 diabetes
NL-OMON43438Phase 4Active, not recruiting
- Sponsor
- University Medical Center Groningen
- Start
- Nov 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of telmisartan, empagliflozin, linagliptin and sulodexide in albuminuria and diabetic glomerulosclerosis, sponsored by University Medical Center Groningen. Primary endpoint: Degree of albuminuria lowering response to four different drug classes. Started Nov 2016; status: active, not recruiting.
02
Drugs
telmisartanempagliflozinlinagliptinsulodexide
03
Conditions
albuminuriadiabetic glomerulosclerosis
Beyond the preview
Go deeper on NL-OMON43438.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON43438.